Literature DB >> 2614489

Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.

K Kaneko1, T Atsumi, T Miyatake.   

Abstract

The activity of detoxication with the cytochrome P450 family of enzymes was studied in patients with amyotrophic lateral sclerosis (ALS). The metabolic ratio (MR) of sparteine sulphate was measured, and the population of phenotypes for sparteine nitro (N)-oxidation was determined in 30 patients with ALS and 41 controls for the assay of the sparteine N-oxidation by the cytochrome P450 enzymes. A lower MR and higher frequency of efficient metabolizers were observed in the ALS group, suggesting that there is efficient sparteine N-oxidation by cytochrome P450 pathways in ALS. This tendency was more marked in 15 patients with ALS aged under 60 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2614489     DOI: 10.1007/bf00328505

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  Xenobiotic metabolism in motor neuron disease.

Authors:  G Steventon; A C Williams; R H Waring; H S Pall; D Adams
Journal:  Lancet       Date:  1988-09-17       Impact factor: 79.321

2.  Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis.

Authors:  Y Nakano; K Hirayama; K Terao
Journal:  Arch Neurol       Date:  1987-01

3.  Evidence for polymorphic oxidation of sparteine in Japanese subjects.

Authors:  T Ishizaki; M Eichelbaum; Y Horai; K Hashimoto; K Chiba; H J Dengler
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 4.  P450 genes: structure, evolution, and regulation.

Authors:  D W Nebert; F J Gonzalez
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

5.  Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

Authors:  A Barbeau; T Cloutier; M Roy; L Plasse; S Paris; J Poirier
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin.

Authors:  P S Spencer; P B Nunn; J Hugon; A C Ludolph; S M Ross; D N Roy; R C Robertson
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.